Erasca (ERAS) concentration risks

The company's concentration profile is defined by two interconnected exposures that together characterize a clinical-stage single-program biotech. The first is pipeline concentration: the AURORAS-1 and BOREALIS-1 Phase 1 trials for ERAS-0015 and ERAS-4001 are the lead clinical programs, with all other programs still in preclinical or discovery stages — a high-share structural exposure. The company's near-term value creation is substantially dependent on advancing these two programs, and any clinical setback, regulatory hold, or failure to demonstrate proof-of-concept in the Phase 1 studies would have a large impact on the enterprise. The second exposure is a supplier dependency: ERAS-0015 is licensed from Guangzhou Joyo Pharmatech Co., Ltd. — a medium-share dependency that adds a licensing and supply-chain dimension to the lead program. The dependency character means that the relationship with Joyo governs the company's ability to develop and eventually commercialize one of its two lead clinical-stage assets, introducing counterparty risk at the development level. The two exposures compound each other: the most advanced programs define the entirety of near-term clinical value, and one of those programs is contingent on a single external licensor. There is no commercial revenue, geographic diversification, or customer base to offset these concentrations. On balance, the profile is that of a concentrated early-clinical biotech where pipeline execution and the Joyo licensing relationship are the primary variables governing the investment outcome.

For the engine’s reasoning on ERAS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.